Updated On: 12 March, 2021 08:20 AM IST | New Delhi | IANS
The licensure of Covaxin has been changed to emergency use authorisation from earlier approved restricted emergency use in clinical trial mode by India`s drug regulatory authority

A senior citizen takes a COVID-19 vaccine shot. Pic/Ashish Raje
Bharat Biotech`s Covaxin has a negligible number of side effects reported among the beneficiaries of the Covid-19 vaccine, NITI Aayog`s Member (Health), V.K. Paul said on Thursday.
"The vaccine has been administered so far to 19 lakh people and only 311 individuals of them have reported minimal side effects.